QUTENZA
Peakcapsaicin
NDATOPICALPATCH
Approved
Nov 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 7m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUTENZA is a topical capsaicin patch approved for neuropathic pain relief, indicated for postherpetic neuralgia and other peripheral neuropathies. Capsaicin depletes substance P, a neuropeptide involved in pain transmission, providing localized analgesia through transdermal delivery. The patch delivers high-concentration capsaicin directly to affected skin, allowing sustained pain relief with minimal systemic absorption.
$0.012BPart D
Peak3.7 years to LOEQUTENZA is in peak commercial stage with modest but stable Part D utilization; career growth opportunities are limited as the product maintains steady-state revenue with small field infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Alcohol Neurolysis and Capsaicin for Postamputation Pain (PAP)
Started Feb 2026
120 enrolled
Postamputation Pain
Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model
Started Jan 2022
24 enrolled
Pain
Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair
Started Sep 2020
34 enrolled
Postsurgical Pain
Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)
Started Dec 2019
193 enrolled
Postsurgical Pain
Capsaicin for Cerebral Perfusion Augmentation.
Started Dec 2019
30 enrolled
Stroke
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.